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Background—The possible association between coronary artery disease (CAD) and Chlamydia pneumoniae (C pneumoniae)
infection is controversial. On the basis of the recent suggestion that mannose-binding lectin (MBL) variant alleles are related
to an increased risk of severe atherosclerosis, and on the in vitro interaction of MBL with C pneumoniae, we asked whether
MBL might contribute to CAD in conjunction with C pneumoniae.
Methods and Results—Antibodies to C pneumoniae were measured by immunofluorescence and MBL alleles were
determined by polymerase chain reaction technique in samples from 210 patients with CAD and 257 healthy subjects
from Hungary collected between 1995 and 1996. A higher percentage of patients with CAD were anti-C pneumoniae
positive as compared with the control group (P0.058). However, at logistic regression analysis adjusted to age, sex,
and serum lipid levels, this difference was confined only to subjects carrying MBL variant alleles (P0.035, odds ratio
2.63, [95% CI: 1.07 to 6.45]). In contrast, no significant difference was seen in those homozygous for the normal MBL
allele (P0.412). During a 655.8-month follow-up period, major outcomes (new myocardial infarction, and/or bypass
operation or cardiovascular death) occurred in 11 C pneumoniae positive and 3 C pneumoniae negative patients. In the
C pneumoniae positive group, the odds ratio of development of outcomes was 3.27 (95% CI: 1.10 to 9.71, P0.033)
in the carriers of the MBL variant alleles compared with the homozygous carriers of the normal MBL allele.
Conclusions—These results indicate that infection with C pneumoniae leads mainly to the development and progression
of severe CAD in patients with variation in the MBL gene. (Circulation. 2002;106:1071-1076.)
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Since the original study by Saikku et al,1 several studieshave indicated an association between Chlamydia pneu-
moniae (C pneumoniae) infection and coronary artery disease
(CAD),2–4 although this field remains highly controversial.5
Mannose-binding lectin (MBL) is a complement-activating
innate immune defense serum protein which binds to man-
nose and acetylglucosamine sugar groups on different micro-
organisms.6 Recent findings indicate that MBL inhibits in-
fection of HeLa cells by different Chlamydia species,7
suggesting that MBL participates in the protection against
C pneumoniae. MBL variant alleles that result in decreased
serum levels of functional MBL are associated with an
increased risk of respiratory infections especially during early
childhood,8 and also with susceptibility and outcome of
infections in adults already weakened by a concomitant
condition like cystic fibrosis.9 Furthermore, we10 and others11
have reported that MBL variant alleles are associated with
accelerated development of severe atherosclerosis.
On the basis of these observations, we asked whether the
association between the presence of C pneumoniae and CAD
and the further progression of severe CAD in patients who
underwent coronary bypass surgery might be associated with
a modifying effect of MBL variant alleles, which cause low
levels of functional MBL in the blood.12–14
Methods
Patients and Controls
The study was performed in 210 Hungarian patients with CAD (50
women and 160 men, aged 58.88.2 years) with signs of severe
stenosis and clinical signs of unstable angina pectoris with typical
ECG changes. Diagnosis was confirmed by coronary angiography.
All patients underwent bypass surgery. Serum and DNA samples
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were collected from the patients between 1995 and 1996. A ques-
tionnaire on the occurrence of different events (death of the patient,
new myocardial infarction, necessity of bypass reoperation, coronary
angioplasty, stroke, carotid endarterectomy, etc) was mailed to each
patient in December 2000. In 4 months, 150 patients sent back filled
questionnaires that could be properly evaluated. By contacting the
family doctors, information on an additional 27 patients was ob-
tained. Thus, in 177 of 210 patients (84.3%) the number and types of
events that occurred during the 655.8-month follow-up period
were known.
Healthy controls included 93 women and 164 men, all Hungarian
(blood donors and volunteers) and aged 46.511.9 years. All control
subjects were examined and asked about any diseases, including
CAD, in their medical history. Only healthy subjects without
suspicion of CAD were enrolled in this study. A history of past and
current cigarette smoking was obtained for each patient and control.
Those who had stopped smoking20 years ago were considered not
to have smoking as a risk factor. Patients were considered to have
hypertension if they had received a diagnosis with an arterial
pressure 140/90 mm Hg. Table 1 lists the demographic variables
and some laboratory data assessed in the patients and control groups.
The review committee of Semmelweis Medical University approved
the study, and the subjects gave informed consent. The patients and
some controls have recently been described.15
Titration of IgG-Type Antibodies Against
C pneumoniae
C pneumoniae-specific IgG antibodies were quantitated in serum
samples diluted 1:128 by microimmunofluorescence assay (ServiMif
Chlamydia S630, Servibio, Meudon, France) according to the man-
ufacturer’s instructions. Sera were designated as positive (titer:
1:128) or weakly positive or negative (titer:1:128), referred to as
negative in the text and tables, on the basis of typical immunofluo-
rescence associated with evenly distributed C pneumoniae organ-
isms. Sera positive for Chlamydia trachomatis or Chlamydia psittaci
were excluded from the study.
Determination of MBL Alleles
MBL variant alleles B (codon 54), C (codon 57), and D (codon 52)
in the mbl2 gene, which disrupts the structure of the protein and
causes a dominant decrease in the functional MBL serum level, were
determined by PCR-based techniques as described.12 The normal
allele is named A, whereas the common designation of the variant
alleles is O. MBL promoter alleles were also analyzed.16
Other Laboratory Tests
C-reactive protein (CRP) serum concentrations were measured by
particle enhanced immunoturbidimetric assay (Roche, Cobas Integra
400). The detection limit of the assay is 0.07 mg/L, the coefficient of
variation 3.9% at 108 mg/L mean value. The amount of IgG-type
antibodies reacting with human hsp60 (Lionex GmbH, Braun-
schweig, Germany) was assessed by ELISA, as described
previously.15
Statistical Analyses
Fisher’s exact test was used to compare frequencies. Mann-Whitney
test was used to compare quantitative data. In some comparisons,
logistic regression analyses were performed. Two-tailed tests were
used throughout.
Results
Basic Characteristics of the Patients and Controls
The average age of the patients was markedly higher than that
of the healthy control subjects (Table 1). Similarly, serum
concentrations of total cholesterol and triglyceride were
significantly higher in the group of patients than in the control
group. The ratio of men to women was higher in the patient
group than among the controls. Body mass index (BMI), as
well as the percentage of smokers and subjects with hyper-
tension, was also significantly higher in the patients than in
the control group. Additionally, a significantly higher per-
centage of the patients were C pneumoniae seropositives
(Table 1).
Frequencies of MBL Variant Alleles in Patients
With CAD and Healthy Controls in Relation
to C pneumoniae Status
Antibodies to C pneumoniae and the frequency of various
MBL alleles were assessed in the 210 patients with CAD and
in the 257 control subjects (Table 2). No significant differ-
ence between C pneumoniae–seropositive and -seronegative
individuals in the frequency of MBL variant alleles was
revealed (P0.75, odds ratio 0.94 [95% CI 0.63 to 1.39]).
However, in C pneumoniae–seropositive subjects, we found
that the carriers of variant MBL alleles (A/O and O/O)
occurred more frequently among patients than controls
(P0.091, odds ratio: 1.48 [0.94 to 2.31]), whereas no differ-
ence between patients with CAD and controls in MBL allele
distribution was observed in the group of C pneumoniae–
seronegative subjects. This observation prompted us to use
multiple logistic regression analysis to study if C pneumoniae
infection is associated with CAD more frequently in carriers
of MBL variant alleles.
Dependence of the Association of C pneumoniae
Seropositivity With Coronary Artery Disease on
the MBL Polymorphisms
Patients were stratified according to MBL alleles, and ho-
mozygous carriers of normal allele (A/A) were compared with
heterozygous and homozygous carriers of the variant MBL
alleles (A/O and O/O) (Table 3). Odds ratios adjusted for
variables that were found to be significantly different at
univariate analysis are shown in Table 1.
For the total number of patients and controls, after adjust-
ment, C pneumoniae positivity was associated with CAD
only with a marginal significance. When only subjects
TABLE 1. Demographic Variables and Laboratory Data in 210
Patients With Severe CAD and in 257 Healthy Controls
Patients With
Severe CAD
(n210)
Healthy
Controls
(n257) P
Age, y 58.88.2 46.511.9 0.0001*
Sex, n, male/female 160/50 164/93 0.005†
Total cholesterol, nmol/L 6.20 (5.50–7.25) 5.59 (4.83–6.40) 0.0001*
Triglyceride, nmol/L 2.00 (1.45–3.10) 1.50 (0.98–2.23) 0.0001*
Smokers, % 58.5 23.9 0.0001†
Hypertension, % 33.3 21.2 0.046†
BMI 0.2850.050 0.2670.041 0.004*
C pneumoniae, n,
positive/negative
157/53 162/95* 0.007†
Values are given as meanSD, median (interquartile range), number of
patients, or percentage of patients.
P calculated with the *Mann-Whitney test and †Fisher’s exact test for the
continuous and categorical variables, respectively.
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carrying MBL variant O alleles were considered, however, a
high (2.62 [1.07 to 6.44]) and significant (P0.035) adjusted
odds ratio of the patients with C pneumoniae positive was
found. Similar results were obtained when the results were
adjusted for age, sex, serum triglyceride concentration, BMI,
as well as for the percentage of smokers and subjects with
hypertension (Table 3). Because there was a significant
(P0.001) interaction between BMI and serum cholesterol
concentrations, it was not possible to put these 2 variables in
the same model. In contrast, no association between C
pneumoniae positivity and CAD was seen in subjects ho-
mozygous for the normal A allele (Table 3).
To further minimize the effect of potentially confounding
factors, 147 patients with severe CAD and 147 controls were
matched for age and sex, and results for C pneumoniae
antibodies in carriers of normal or variant MBL alleles were
TABLE 2. Occurrence of MBL Alleles Stratified According to C pneumoniae
Antibody Status in 210 Patients With Coronary Heart Disease and 257 Controls
MBL
Genotype*
C pneumoniae Positive C pneumoniae Negative All Subjects
Patients
Healthy
Controls Patients
Healthy
Controls Patients
Healthy
Controls
A/A 83 (52.9) 101 (62.3) 35 (66.0) 48 (50.5) 118 (56.2) 149 (58.0)
A/B 45 (28.7) 30 (18.5) 9 (17.0) 27 (28.4) 54 (25.7) 57 (22.2)
A/C 5 (3.2) 6 (3.7) 0 (0.0) 2 (2.1) 5 (2.4) 8 (3.1)
A/D 19 (12.1) 17 (10.5) 6 (11.3) 8 (8.4) 25 (11.9) 25 (9.7)
Total A/O 69 (43.9) 53 (32.7) 15 (28.3) 37 (38.9) 84 (40.0) 90 (35.0)
B/B 2 (1.3) 3 (1.9) 0 (0.0) 2 (2.1) 2 (1.0) 5 (1.9)
B/C 1 (0.6) 0 (0.0) 0 (0.0) 3 (3.2) 1 (0.5) 3 (1.2)
B/D 1 (0.6) 3 (1.9) 0 (0.0) 2 (2.1) 1 (0.5) 5 (1.9)
C/C 0 (0.0) 1 (0.6) 0 (0.0) 1 (1.1) 0 (0.0) 2 (0.8)
C/D 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.1) 0 (1.9) 2 (0.8)
D/D 1 (0.6) 1 (0.6) 3 (5.7) 0 (1.2) 4 (1.9) 1 (0.4)
Total O/O 5 (3.2) 8 (4.9) 3 (5.7) 10 (10.5) 8 (3.8) 18 (7.0)
A/0  0/0 74 (47.1) 61 (37.7) 18 (34.0) 47 (49.5) 92 (43.8) 108 (42.0)
Sum 157 (100.0) 162 (100.0) 53 (100.0) 95 (100.0) 210 (100.0) 257 (100.0)
O allele
frequency
0.25 0.21 0.20 0.30 0.24 0.25
Values are given as n (%).
*A indicates normal MBL allele; allele O, the variant alleles B (codon 54), C (codon 57), and D
(codon 52).
TABLE 3. Logistic Regression Analysis for the Association Between the Prevalence of Anti-C pneumoniae Antibodies
and CAD in 210 Patients With Severe CAD and 257 Healthy Controls Stratified According to MBL Genotypes
C pneumoniae Status
Patients,
n (%)
Healthy
Controls,
n (%)
Odds Ratio
(95% CI) P
Model 1,*
Adjusted Odds
Ratio (95% CI) P
Model 2,†
Adjusted Odds
Ratio (95% CI) P
All subjects
Positive 157 (74.8) 162 (62.3)
Negative 53 (25.2) 95 (37.7) 1.74 (1.14–2.65) 0.0067 1.78 (0.98–3.12) 0.058 1.80 (0.55–5.93) 0.336
Sum 210 (100.0) 257 (100.0)
Subjects homozygous for the
normal (A/A) MBL alleles
Positive 83 (70.3) 101 (64.9)
Negative 35 (29.7) 48 (35.3) 1.13 (0.65–1.97) 0.65 1.39 (0.64–3.02) 0.412 0.64 (0.09–4.53) 0.640
Sum 118 (100.0) 149 (100.0)
Subjects heterozygous and homozygous
for the variant (A/0 and 0/0) MBL alleles
Positive 74 (80.4) 61 (58.5)
Negative 18 (19.6) 47 (41.5) 3.34 (1.69–6.66) 0.0002 2.63 (1.07–6.45) 0.035 7.98 (1.07–59.24) 0.043
Sum 92 (100.0) 108 (100.0)
*Adjusted for age, sex, serum cholesterol, and triglyceride concentration.
†Adjusted for age, sex, serum triglyceride concentration, BMI, percentage of smokers, and hypertension.
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compared (Table 4). The average age (54.96.3 years for the
patients and 53.67.7 years for controls) was almost identi-
cal (P0.119), and the distribution of men and women did
not differ significantly (P0.1) in the groups of patients
(110/37) and matched controls (96/51). Similar to the results
obtained in the whole study population, CAD was associated
with C pneumoniae positivity only in subjects carrying the
MBL variant alleles, even when matched pairs were com-
pared by logistic regression analysis adjusted to the serum
cholesterol and triglyceride concentrations (Table 4).
Genotyping for MBL promoter alleles (not shown) was not
additionally informative.
Predictive Value of Polymorphisms of the MBL
of the Major Outcomes With Severe CAD in the
C pneumoniae–Positive and C pneumoniae–
Negative Patients
One hundred and seventy seven of 210 patients (84.3%) could
be monitored up for 655.8 months. We calculated the
predictive value of the MBL polymorphisms on the develop-
ment of major outcomes of CAD (new myocardial infarction
and/or new bypass operation and/or cardiovascular death).
Altogether, 12 patients developed myocardial infarction, and
bypass operation was performed on an additional patient who
did not develop myocardial infarction in the meantime. An
additional patient died of heart attack without previous
myocardial infarction or bypass operation. Therefore, major
outcomes occurred in 14 patients during the follow-up period.
These patients were divided according to MBL polymor-
phisms and C pneumoniae serostatus measured in the base-
line serum samples and predictive values of these variables
were determined with the use of multiple logistic regression
analysis. We also adjusted the analysis to other variables that
may affect the outcomes (Table 5). Major outcomes occurred
more frequently in the carriers of the variant MBL alleles
(adjusted odds ratio: 2.40 [95% CI 0.96 to 5.96], P0.060).
This association was, however, restricted to the patients
positive with C pneumoniae. In this group, 9 events occurred
in 11 carriers of the variant alleles. The MBL variant allele
carriers had a 3.27 (CI: 1–10 –9.71, P0.033) higher
adjusted odds ratio to develop major outcomes than non-
carriers. By contrast MBL polymorphisms did not predict the
development of events in patients negative for C pneumoniae
(Table 5).
Lack of Association Between MBL Polymorphisms
and Serum Concentration of CRP and IgG
Antibodies to hsp60
We compared serum concentrations of CRP and IgG anti-
hsp60 in homozygous carriers of the wild MBL allele with
carriers of the variant MBL alleles. We did not find signifi-
cant differences between the 2 groups: CRP concentrations
(median (25th-75th percentile) was 4.06 (1.88 to 7.30) mg/L
and 3.14 (1.83 to 6.79) mg/L, respectively (P0.572). Serum
concentrations of anti-hsp60 antibodies were 103 (46 to 192)
AU/mL and 87 (39 to 204) AU/mL, respectively (P0.576).
Similar results were obtained when subjects both positive and
negative for C pneumoniae were analyzed separately.
Discussion
This study supports the association between C pneumoniae
infection and CAD; however, the association was solely
dependent on individual variation in the MBL gene (mbl2).
No increased risk was seen in individuals homozygous for the
normal MBL allele, although a significant risk characterized
individuals with MBL variant alleles, even after adjustment
for age, sex, serum lipid concentrations, BMI, as well as for
the percentage of smokers and occurrence of hypertension.
Moreover, during a follow-up period of 5.5 years, a 3-fold
increased risk of a major cardiovascular event was observed
TABLE 4. Logistic Regression Analysis of the Association Between the Prevalence of Anti–C pneumoniae
Antibodies and CAD in 147 Patients and 147 Age and Sex-Matched Healthy Controls Stratified According to
MBL Genotypes
C pneumoniae Status
Patients,
n (%)
Healthy
Controls,
n (%)
Odds Ratio
(95% CI) P
Adjusted* Odds
Ratio (95% CI) P
All subjects
Positive 115 (78.2) 93 (63.2)
Negative 32 (21.8) 54 (36.7) 2.09 (1.25–3.50) 0.005 1.93 (1.10–3.39) 0.021
Sum 147 (100.0) 147 (100.0)
Subjects homozygous for the normal
(A/A) MBL allele
Positive 63 (75.0) 54 (67.5)
Negative 21 (25.0) 26 (32.5) 1.44 (0.73–2.83) 0.289 1.44 (0.68–3.06) 0.343
Sum 84 (100.0) 80 (100.0)
Subjects heterozygous and homozygous for
the variant MBL allele (A/O and O/O)
Positive 52 (82.5) 39 (58.2)
Negative 11 (17.5) 28 (41.8) 3.94 (1.51–7.64) 0.003 2.88 (1.10–3.39) 0.016
Sum 63 (100.0) 67 (100.0)
*Adjusted to the serum total cholesterol and triglyceride levels.
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in MBL variant alleles carriers (provided that they were
positive for C pneumoniae) compared with homozygous
carriers of the normal MBL allele.
Thus, C pneumoniae infection may lead to the develop-
ment of severe CAD in genetically predisposed individuals
carrying MBL variant alleles. These findings are consistent
with previous observations indicating that MBL variant
alleles are associated with severe CAD10 and with increased
carotid plaque areas.11 C pneumoniae status was not assessed
in either study. Moreover, if reproduced, the present findings
should also help to clarify much of the inconsistency in
literature about C pneumoniae and CAD.5 A relatively small
odds ratio because of the high frequency of infected individ-
uals in the background population might undoubtedly lead to
miscellaneous results in different studies because of varia-
tions in additive parameters leading to vascular pathology.
MBL deficiency has been implicated in C pneumoniae
infection because the bacteria carry the sugar structures
relevant for MBL binding.7 Moreover, MBL inhibits the
uptake of the bacteria to target cells in vitro.7 We did not
observe a direct protective effect of MBL against C pneu-
moniae per se, which is not unexpected because the sero-
prevalence in healthy adults exceeds 60%. Almost all indi-
viduals are probably infected with C pneumoniae during their
lifetime and many are reinfected.17 Moreover, MBL is not
present in the normal lung.9,18 Therefore, MBL may act to
modulate the severity of the infection, rather than protect
against it, as previously suggested.10 For example, MBL
might inhibit the dissemination of C pneumoniae from the
lungs by monocytes/macrophages to the blood stream and
subsequently to the vascular wall. Alternatively, or in addi-
tion, MBL might modulate the inflammatory response initi-
ated by chronic infection with C pneumoniae or other stimuli
in the atherosclerotic plaque. Experimental studies support
such a view in which it has been shown that MBL may
modulate cytokine responses.19 We have previously shown
that MBL in vivo can exert a striking modulating effect on
inflammation associated with rheumatoid arthritis.20 Never-
theless, the present results indicate that C pneumoniae in
general may be a rather harmless bacteria in relation to the
atherosclerotic process and that an additional component,
such as MBL deficiency, is necessary for clinically relevant
pathology. This conclusion is in line with the evidence from
animal models indicating that it is difficult to induce athero-
sclerosis with C pneumoniae alone, but that the microorgan-
ism acts in conjunction with other atherosclerotic risk fac-
tors.21 Some studies suggest a direct inflammatory role of
complement in atherogenesis mediated through the binding of
CRP to degraded, nonoxidized LDL, enhancing complement
activation associated with vascular pathology.22,23 According
to the present study, however, interaction of MBL poly-
morphisms and C pneumoniae infection does not exert its
effect on CAD development either through CRP or anti-
hsp60 antibodies.
A dual role of MBL in CAD has been suggested, on the
basis of the exposure of MBL ligands through oxidative stress
of endothelial cells, a model of ischemia/reperfusion injury.24
Moreover, MBL and complement factor C3 immunostaining
was found throughout an ischemic area after rat myocardial
reperfusion.24 Thus, MBL might partly protect against severe
atherosclerosis in conjunction with C pneumoniae or other
related conditions, but this relative advantage may be turned
in to a disadvantage during revascularization procedures.
This study indicates that MBL deficiency may represent an
important factor in connection with C pneumoniae infection
in the development of CAD and disease progression. How-
ever, the relatively small size and lack of supportive biolog-
ical data make it necessary that these observations are
TABLE 5. Predictive Value Calculated Logistic Regression of MBL Genotypes Influence on
the Major Outcomes in the C pneumoniae—Positive and—Negative patients (at Baseline) With
Severe CAD
MBL Alleles
New Myocardial Infarction and/or
Bypass Operation and/or
Cardiovascular Death
Odds Ratio
(95% CI) (P)
Adjusted* Odds Ratio
(95% CI) (P)Yes No
C pneumoniae positive
Normal A/A† 2 68 5.28 (1.10–25.4) (0.029) 3.27 (1.10–9.71) (0.033)
Variant A/O or O/O† 9 58
Total 11 126
C pneumoniae negative
Normal A/A† 2 24 0.92 (0.08–11.20) (1.00) 0.86 (0.08–8.89) (0.896)
Variant A/O or O/O† 1 13
Total 3 37
All patients
Normal A/A† 4 92 3.24 (0.97–10.70) (0.053) 2.40 (0.96–5.96) (0.060)
Variant A/O or O/O† 10 71
Total 14 163
*Adjusted to extent of stenosis of coronary arteries, occurrence of previous myocardial infarction, as well as
baseline serum total cholesterol and triglyceride levels by logistic regression.
†See Table 2 for explanation.
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confirmed in additional prospective studies before definitive
conclusions can be drawn. If confirmed, the results suggest
that determination of the MBL genetic status in C pneumoniae–
seropositive CAD patients may serve to identify those patients
more likely to benefit from antibiotic therapy.
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